Phase 1/2, Single-Arm, Open-Label Trial to Evaluate the Safety, Feasibility, and Immunogenicity of Ex Vivo CRISPR-Cas9 Gene-Edited Donor Kidneys (Knockout of HLA-A, HLA-B, and CIITA) in Human Renal Transplant Recipients is a PHASE1 clinical asset sponsored by AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC in End-Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Renal Disease With Renal Transplant, Kidney Transplant Rejection, Kidney Tumor, Kidney Failure, Kidney Ischemia. SEO and diligence focus: Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney, Kidney Transplantation with Standard Care, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.